Nykode Therapeutics AS (NYKD.OL)
NOK 3.19
(-4.61%)
NOK 3.19
(-4.61%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 136.38 Million USD | 97.76% |
| 2022 | 68.96 Million USD | -76.39% |
| 2021 | 292.03 Million USD | -85.57% |
| 2020 | 2.02 Billion USD | 143805.44% |
| 2019 | -1.4 Million USD | 98.19% |
| 2018 | -77.75 Million NOK | -79.79% |
| 2017 | -43.24 Million NOK | -71.86% |
| 2016 | -25.16 Million NOK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 544 Thousand USD | -34.22% |
| 2024 Q1 | 8.7 Million USD | -58.98% |
| 2023 FY | 136.38 Million USD | 97.76% |
| 2023 Q2 | 53.58 Million USD | 67.28% |
| 2023 Q3 | 28.93 Million USD | -46.01% |
| 2023 Q4 | 23.74 Million USD | -17.95% |
| 2023 Q1 | 32.03 Million USD | 16.87% |
| 2022 Q2 | 29.4 Million NOK | 364.85% |
| 2022 FY | 68.96 Million USD | -76.39% |
| 2022 Q4 | 27.4 Million USD | 323.29% |
| 2022 Q3 | 6.47 Million NOK | -77.98% |
| 2022 Q1 | 6.32 Million NOK | -97.66% |
| 2021 Q4 | 269.88 Million NOK | 2976.22% |
| 2021 FY | 292.03 Million USD | -85.57% |
| 2021 Q3 | 8.77 Million NOK | 0.0% |
| 2020 FY | 2.02 Billion USD | 143805.44% |
| 2019 FY | -1.4 Million USD | 98.19% |
| 2018 FY | -77.75 Million NOK | -79.79% |
| 2017 FY | -43.24 Million NOK | -71.86% |
| 2016 FY | -25.16 Million NOK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Arctic Bioscience AS | 9.77 Million NOK | -1295.394% |
| Aqua Bio Technology ASA | 607.92 Thousand NOK | -22333.632% |
| ArcticZymes Technologies ASA | 113.01 Million NOK | -20.676% |
| BerGenBio ASA | 354 Thousand NOK | -38425.453% |
| Hofseth BioCare ASA | 29.87 Million NOK | -356.472% |
| PCI Biotech Holding ASA | 2.99 Million NOK | -4461.207% |
| Thor Medical ASA | - NOK | -Infinity% |
| Ultimovacs ASA | -2.76 Million NOK | 5027.027% |